MX2022003017A - Uso de un agonista del receptor de orexina 2 para tratamiento de somnolencia excesiva. - Google Patents

Uso de un agonista del receptor de orexina 2 para tratamiento de somnolencia excesiva.

Info

Publication number
MX2022003017A
MX2022003017A MX2022003017A MX2022003017A MX2022003017A MX 2022003017 A MX2022003017 A MX 2022003017A MX 2022003017 A MX2022003017 A MX 2022003017A MX 2022003017 A MX2022003017 A MX 2022003017A MX 2022003017 A MX2022003017 A MX 2022003017A
Authority
MX
Mexico
Prior art keywords
treatment
orexin
receptor agonist
excessive sleepiness
compound
Prior art date
Application number
MX2022003017A
Other languages
English (en)
Spanish (es)
Inventor
Deborah Hartman
Rebecca Evans
Helene Faessel
Shinichiro Tanaka
Robert Rubens
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MX2022003017A publication Critical patent/MX2022003017A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2022003017A 2019-09-13 2020-09-12 Uso de un agonista del receptor de orexina 2 para tratamiento de somnolencia excesiva. MX2022003017A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962900310P 2019-09-13 2019-09-13
US202063031687P 2020-05-29 2020-05-29
PCT/IB2020/058482 WO2021048821A1 (en) 2019-09-13 2020-09-12 Use of an orexin 2 receptor agonist for the treatment of excessive sleepiness

Publications (1)

Publication Number Publication Date
MX2022003017A true MX2022003017A (es) 2022-06-14

Family

ID=72521681

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003017A MX2022003017A (es) 2019-09-13 2020-09-12 Uso de un agonista del receptor de orexina 2 para tratamiento de somnolencia excesiva.

Country Status (11)

Country Link
US (1) US20220331303A1 (https=)
EP (1) EP4028003A1 (https=)
JP (1) JP2022547604A (https=)
KR (1) KR20220062361A (https=)
CN (1) CN114555083A (https=)
AU (1) AU2020347578A1 (https=)
BR (1) BR112022004576A2 (https=)
CA (1) CA3154320A1 (https=)
CO (1) CO2022004589A2 (https=)
MX (1) MX2022003017A (https=)
WO (1) WO2021048821A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4065585B1 (en) 2019-11-25 2025-08-20 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
AU2021205892B2 (en) 2020-01-10 2026-04-23 Takeda Pharmaceutical Company Limited A method for enhancing the pharmacokinetics or increasing the plasma concentration of methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof with an inhibitor of cytochrome P450
CN116583502A (zh) 2020-09-03 2023-08-11 欧瑞夏治疗有限公司 二环-杂环衍生物及其作为食欲素-2受体激动剂的用途
US12006330B2 (en) 2020-12-21 2024-06-11 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
WO2024075825A1 (ja) 2022-10-07 2024-04-11 キッセイ薬品工業株式会社 シクロペンタン化合物
EP4719397A1 (en) * 2023-06-02 2026-04-08 Takeda Pharmaceutical Company Limited Use of an orexin 2 receptor agonist for improving respiratory function during sleep
WO2025124698A1 (en) 2023-12-12 2025-06-19 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators
TW202542165A (zh) 2023-12-19 2025-11-01 瑞士商愛杜西亞製藥有限公司 大環食慾素激動劑

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0815134B1 (en) 1995-03-14 2002-06-05 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
PT929574E (pt) 1996-08-27 2005-11-30 Praecis Pharm Inc Moduladores da agregacao de peptidos beta-amiloides compreendendo d-aminoacidos
EP1196609A2 (en) 1999-06-28 2002-04-17 Oklahoma Medical Research Foundation Catalytically active recombinant memapsin and methods of use thereof
LT3984994T (lt) * 2016-02-04 2024-10-10 Takeda Pharmaceutical Company Limited Pakeistas piperidino junginys kaip 2 tipo oreksino agonistas narkolepsijai gydyti
JOP20190008A1 (ar) * 2016-07-26 2019-01-24 Purdue Pharma Lp علاج ومنع اضطرابات النوم
AU2020346456A1 (en) * 2019-09-13 2022-04-14 Takeda Pharmaceutical Company Limited TAK-925 for use in treating narcolepsy

Also Published As

Publication number Publication date
US20220331303A1 (en) 2022-10-20
KR20220062361A (ko) 2022-05-16
CA3154320A1 (en) 2021-03-18
JP2022547604A (ja) 2022-11-14
EP4028003A1 (en) 2022-07-20
CO2022004589A2 (es) 2022-04-29
WO2021048821A1 (en) 2021-03-18
CN114555083A (zh) 2022-05-27
WO2021048821A8 (en) 2021-11-04
AU2020347578A1 (en) 2022-04-14
BR112022004576A2 (pt) 2022-06-14

Similar Documents

Publication Publication Date Title
MX2022003017A (es) Uso de un agonista del receptor de orexina 2 para tratamiento de somnolencia excesiva.
CL2021002880S1 (es) Estuche de auriculares. (divisional solicitud 202000595)
GEP20227443B (en) Magl inhibitors
MY209489A (en) Antibody against human il-4ra and use thereof
ZA202003386B (en) Il-2 muteins and uses thereof
EP4616912A3 (en) Phosphoalkyl ribose polymers comprising biologically active compounds
MX2022007968A (es) Dosificacion de gamma-hidroxibutirato (ghb).
ZA202106602B (en) Claudin 6 antibodies and uses thereof
MX2018015251A (es) Derivados de 2-amino-4-(amino sustituido)fenil carbamato fluorinado.
EP3768677A4 (en) COMPOSITIONS OF KV7 CHANNEL ACTIVATORS AND METHOD OF USE
MX2021002065A (es) Metodos, productos y usos relacionados con la depuracion de especies acidas de sulfuro.
MX2019011116A (es) Inhibidores de la tirosina quinasa de bruton.
MX2022011077A (es) Variantes de transglutaminasa.
PH12022550937A1 (en) Pharmaceutical composition comprising selexipag
CR20220255A (es) Inhibidores de egfr
EP3942646A4 (en) CARBON AIRGEL BASED CATHODE FOR LITHIUM AIR BATTERIES
EP3962533A4 (en) PLATFORM FOR THROAT ADMINISTRATION AND USES THEREOF
MX2020013170A (es) Composicion agricola.
EP3973550C0 (en) PEPTIDE IONOGEL, COMPOSITION, METHODS AND USES THEREOF
CL2022001361A1 (es) Composiciones antimicrobianas que comprenden arcilla modificada y copolímeros.
SA521422309B1 (ar) أجسام مضادة ناهضة لكيناز تيروسين 3 يشبه ساركوما فيلين ماكدونو واستخداماتها
EP4007578A4 (en) SUBSTITUTED CYCLOPROPYL-2,2'-BIPYRIMIDINYL COMPOUNDS, ANALOGS THEREOF AND METHODS THEREOF
WO2021080931A8 (en) Solid forms comprising (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and salts thereof, and compositions comprising the same and their use
GEAP202515534A (en) Delamanid-containing composition
MX2021002067A (es) Metodos, productos y usos relacionados con la depuracion de especies acidas de sulfuro.